首页> 美国卫生研究院文献>PPAR Research >Peroxisome Proliferator-Activated Receptors and Progression of Colorectal Cancer
【2h】

Peroxisome Proliferator-Activated Receptors and Progression of Colorectal Cancer

机译:过氧化物酶体增殖物激活受体与结直肠癌的进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily. These receptors are also ligand-dependent transcription factors responsible for the regulation of cellular events that range from glucose and lipid homeostases to cell differentiation and apoptosis. The importance of these receptors in lipid homeostasis and energy balance is well established. In addition to these metabolic and anti-inflammatory properties, emerging evidence indicates that PPARs can function as either tumor suppressors or accelerators, suggesting that these receptors are potential candidates as drug targets for cancer prevention and treatment. However, conflicting results have emerged regarding the role of PPARs on colon carcinogenesis. Therefore, further investigation is warranted prior to considering modulation of PPARs as an efficacious therapy for colorectal cancer chemoprevention and treatment.
机译:过氧化物酶体增殖物激活受体(PPAR)是核激素受体超家族的成员。这些受体也是依赖配体的转录因子,负责调节从葡萄糖和脂质稳态酶到细胞分化和凋亡的细胞事件。这些受体在脂质稳态和能量平衡中的重要性已得到充分确立。除了这些代谢和抗炎特性外,新出现的证据表明PPAR既可以充当抑癌剂也可以充当促进剂,这表明这些受体可能是预防和治疗癌症的潜在药物。但是,关于PPAR在结肠癌发生中的作用,已经出现了矛盾的结果。因此,在考虑将PPAR调节作为一种用于大肠癌化学预防和治疗的有效疗法之前,有必要进行进一步的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号